Spero Therapeutics (NASDAQ:SPRO) Announces Quarterly Earnings Results

Spero Therapeutics (NASDAQ:SPRO) issued its quarterly earnings results on Monday. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01, Zacks reports. The business had revenue of $10.20 million for the quarter, compared to the consensus estimate of $9.80 million. Spero Therapeutics had a return on equity of 35.42% and a net margin of 21.09%. During the same period in the prior year, the firm posted ($0.23) earnings per share.

Spero Therapeutics Stock Performance

SPRO stock traded down $0.04 during midday trading on Wednesday, reaching $1.23. The stock had a trading volume of 159,422 shares, compared to its average volume of 222,329. The firm has a fifty day simple moving average of $1.38 and a two-hundred day simple moving average of $1.51. Spero Therapeutics has a 52-week low of $0.99 and a 52-week high of $1.89. The stock has a market cap of $66.41 million, a PE ratio of 2.97 and a beta of 0.63.

Analysts Set New Price Targets

SPRO has been the topic of several research analyst reports. TD Cowen upgraded Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Spero Therapeutics in a research report on Tuesday.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.